<DOC>
	<DOCNO>NCT00506402</DOCNO>
	<brief_summary>The main objective study evaluate side effect MKC-1 determine safe dose MKC-1 future study patient hematological malignancy</brief_summary>
	<brief_title>A Phase 1 Study MKC-1 Patients With Refractory Hematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Metaplasia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<criteria>1 . Patients must relapsed/refractory leukemias standard therapy anticipate result durable remission . Patients poorrisk myelodysplasia ( MDS ) [ i.e . IPSS â‰¥ 1.5 chronic myelomonocytic leukemia ( CMML ) also candidate protocol . Relapsed/refractory leukemias include acute nonlymphocytic leukemia ( AML ) WHO classification , acute lymphocytic leukemia ( ALL ) , chronic lymphocytic leukemia ( CLL ) , chronic myelogenous leukemia ( CML ) blast crisis . Patients agnogenic myeloid metaplasia ( AMM ) also eligible . 2 . Age &gt; 18 year . 3 . ECOG performance status 02 . 4 . In absence rapidly progress disease , interval prior treatment time study drug administration least 2 week cytotoxic agent , least 5 halflives noncytotoxic agent . If patient hydroxyurea control peripheral blood leukemic cell count , patient must hydroxyurea least 48 hour initiation treatment protocol . 5 . Persistent clinically significant chronic toxicity prior chemotherapy , surgery radiotherapy must resolve NCI CTCAE Grade &lt; 1 , except alopecia . 6 . The following laboratory result , within 10 day MKC1 administration ( unless abnormality consider attributable leukemia ) : Serum creatinine &lt; 2.0 mg/dL Total bilirubin &lt; ULN ( unless diagnosis Gilbert 's disease present ) AST &lt; 2.5 x ULN ( upper limit normal ) Serum albumin &gt; 3.0 g/dL 7 . Signed informed consent . 1 . Preexisting hepatomegaly disease measure &gt; 2 cm costal margin , secondary malignancy . 2 . Pregnant breastfeed woman . Female patient must postmenopausal , surgically sterile must agree use physical method contraception . Female patient childbearing potential must negative pregnancy test within 10 day first MKC1 administration . Male patient must surgically sterile agree use acceptable method contraception . Pregnant nursing patient exclude effect MKC1 fetus nursing child unknown . 3 . Clinical evidence bowel obstruction , active uncontrolled malabsorption syndrome history total gastrectomy . 4 . Impaired cardiac function include myocardial infarction within previous 3 month , symptomatic coronary artery disease , arrhythmias control medication , uncontrolled congestive heart failure . 5 . Patients receive standard investigational cytotoxic treatment hematologic malignancy . 6 . Treatment antiretroviral therapy metabolize CYP3A4 ( include indinavir , nelfinavir , ritonavir saquinavir ) due potential drug interaction wth MKC1 . 7 . Any medical condition , investigator 's opinion , would impose excessive risk patient . Examples condition include congestive heart failure Class III IV NYHA classification , active infection , psychiatric condition would interfere understand informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Adult patient refractory leukemia , MDS AMM</keyword>
</DOC>